OMER running up 9% today. Some more information:

Shares of Omeros Corp (OMER) are trading 9% higher at a price of $4.86 at the time of this writing.

The company just announced that that their drug, OMS906, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has received orphan drug designation from the FDA.

Omeros Corp has been trading between a 52-week high of $16.57 and a 52-week low of $1.86. The stock has a market cap of $305 Million.

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.